IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v41y2018i12d10.1007_s40264-018-0704-9.html
   My bibliography  Save this article

Proton Pump Inhibitor Use and Risk of Developing Alzheimer’s Disease or Vascular Dementia: A Case–Control Analysis

Author

Listed:
  • Patrick Imfeld

    (University of Basel
    University Hospital Basel)

  • Michael Bodmer

    (Zuger Kantonsspital)

  • Susan S. Jick

    (Boston Collaborative Drug Surveillance Program
    Boston University School of Public Health)

  • Christoph R. Meier

    (University of Basel
    University Hospital Basel
    Boston Collaborative Drug Surveillance Program)

Abstract

Introduction Long-term use of proton pump inhibitors (PPIs) has been associated with an increased risk of Alzheimer’s disease (AD) in observational studies. The role of exposure duration, and whether this applies to other dementia subtypes, has not been explored in these studies. Objective The aim was to study the association between long-term use of PPIs (or of histamine-2 receptor antagonists [H2RAs], as a negative control) and the risk of developing AD or vascular dementia (VaD). Methods We conducted a case–control analysis on the UK-based Clinical Practice Research Datalink (CPRD). We identified 41,029 patients aged ≥ 65 years with newly diagnosed AD or VaD between 1998 and 2015 and matched them 1:1 to dementia-free controls on age, sex, calendar time, general practice, and number of years of recorded history. We applied conditional logistic regression analyses to calculate adjusted odds ratios (aORs), with 95% confidence intervals (CIs), of developing AD or VaD in relation to previous use of PPIs or H2RAs, categorized by exposure duration. Results As compared to non-use, long-term PPI use (≥ 100 prescriptions) was not associated with an increased risk of developing AD (aOR 0.88, 95% CI 0.80–0.97) or VaD (aOR 1.18, 95% CI 1.04–1.33). Neither was long-term use of H2RAs (≥ 20 prescriptions) associated with an increased risk of developing AD (aOR 0.94, 95% CI 0.87–1.02) or VaD (aOR 0.99, 95% CI 0.89–1.10). Conclusion In this large, case-control analysis, we did not find any evidence for an increased risk of either AD or VaD related to PPI or H2RA use.

Suggested Citation

  • Patrick Imfeld & Michael Bodmer & Susan S. Jick & Christoph R. Meier, 2018. "Proton Pump Inhibitor Use and Risk of Developing Alzheimer’s Disease or Vascular Dementia: A Case–Control Analysis," Drug Safety, Springer, vol. 41(12), pages 1387-1396, December.
  • Handle: RePEc:spr:drugsa:v:41:y:2018:i:12:d:10.1007_s40264-018-0704-9
    DOI: 10.1007/s40264-018-0704-9
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-018-0704-9
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40264-018-0704-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Liang-Yu Chen & Huey-Juan Lin & Wen-Tung Wu & Yong-Chen Chen & Cheng-Li Chen & Jing Kao & San-Lin You & Yu-Ching Chou & Chien-An Sun, 2020. "Clinical Use of Acid Suppressants and Risk of Dementia in the Elderly: A Pharmaco-Epidemiological Cohort Study," IJERPH, MDPI, vol. 17(21), pages 1-12, November.
    2. Ya Qi Song & Yong Li & Su Li Zhang & Jie Gao & Shun Yi Feng, 2019. "Proton pump inhibitor use does not increase dementia and Alzheimer’s disease risk: An updated meta-analysis of published studies involving 642305 patients," PLOS ONE, Public Library of Science, vol. 14(7), pages 1-9, July.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:41:y:2018:i:12:d:10.1007_s40264-018-0704-9. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.